Tests an automated insulin system for type 1 diabetes in adults
Tests a device that delivers insulin automatically in adults with type 1 diabetes.
Key facts
- Who runs it
- Oregon Health and Science University
- Where
- Portland, United StatesSee the site
- Trial code
- Registry title
- Closed Loop Context Aware AID
- Status
- Recruiting
- People taking part
- 10 people, planned
- Started
- 22 Nov 2024
- Planned end
- 30 Aug 2025
- Type of study
- Interventional
- Treatments tested
- iPancreas automated insulin delivery system
- Record updated
- 11 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes who already use a hybrid closed loop insulin system. It tests a new high blood sugar detection and dosing algorithm.
- Age
- 18 years and older (up to 100 years)
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes for at least 1 year, with HbA1c or GMI of 7.0% (53 mmol/mol) or higher at screening.
- Earlier treatment
- Must have used an FDA-approved hybrid closed loop system for 3 months or more. Total daily insulin must be less than 139 units/day.
- Biomarker or test result
- HbA1c or GMI of 7.0% (53 mmol/mol) or higher at screening. GMI or A1c must not be below 6.5% (48 mmol/mol) or above 10.5% (91 mmol/mol).
Main reasons for not taking part
- Pregnant, planning pregnancy or breast-feeding
- Any cardiovascular disease, or kidney (GFR < 60 ml/min) or liver disease
- Severe low blood sugar or diabetic ketoacidosis in the past 6 months
- Use of corticosteroids, beta blockers, or glucose-lowering drugs other than insulin (metformin only if the dose is stable)
- Allergy to Fiasp insulin
The registry criteria, word for word
Show all 40 criteriaShow less
Who can take part
- Diagnosis of type 1 diabetes mellitus for at least 1 year
- Male or female participants 18 and older
- HbA1c or GMI ≥ 7.0% at screening
- Physically willing and able to perform 30 min of exercise (as determined by the investigator after reviewing the participant's activity level)
- Current use of an FDA-approved hybrid closed loop system for ≥3 months
- Lives with another person age 18 or older who will sleep in the house at night and that can attend the training on using the system
- Lives within 40 miles of OHSU
- Total daily insulin requirement is less than 139 units/day
- Able to read, write and understand spoken English
- Current use of a smartphone so can be contacted by study staff off-campus
- Willingness to follow all study procedures, including attending all clinic visits
- Willingness to sign informed consent and HIPAA documents
Who cannot take part
- History of severe hypoglycemia during the past 6 months prior to screening visit or hypoglycemia unawareness as judged by the investigator. Participants will complete a hypoglycemia awareness questionnaire. Participants will be excluded for four or more R responses
- History of diabetes ketoacidosis during the prior 6 months prior to screening visit, as diagnosed on hospital admission or as judged by the investigator
- Known or suspected abuse of alcohol, narcotics, or illicit drugs
- Major surgical operation within 30 days prior to screening
- Use of an investigational drug within 30 days prior to screening
- Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus)
- Current administration of oral or parenteral corticosteroids
- Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia judged by the investigator to be exclusionary
- Liver failure, cirrhosis, or any other liver disease that compromises liver function as determined by the investigator
- Adrenal insufficiency
- Any active infection (example skin infection requiring antibiotics)
- Seizure disorder
- Peripheral arterial disease
- Allergy to Fiasp insulin
- Any life threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer)
- A positive response to any of the questions from the Physical Activity Readiness Questionnaire with one exception: participant will not be excluded if he/she takes a single blood pressure medication that doesn't impact heart rate and blood pressure is controlled on the medication (blood pressure is less than 140/90 mmHg)
- Any clinically significant disease or disorder which in the opinion of the Investigator may jeopardize the participant's safety or compliance with the protocol
- Sensor glucose shows < 2% of time above 250 mg/dl in last 30 days
- Renal insufficiency (GFR < 60 ml/min, using the MDRD equation as reported by the OHSU laboratory)
- Bleeding disorder or platelet count below 50,000
- Use of beta blockers or non-dihydropyridine calcium channel blockers
- Current use of any medication that can lower glucose other than insulin (ex. Wegovy, Jardiance) with the exception of metformin if dose has been stable for ≥3 months and patient willing to not change dose during study
- GMI or A1c <6.5% or >10.5%
- Individual of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence
- Active foot ulceration
- Gastroparesis
- Diet consisting of less than 50 grams of carbohydrates per day
- Any chest discomfort with physical activity, including pain or pressure, or other types of discomfort
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in United States
- Oregon Health and Science UniversityPortland, United StatesContact: Leah Wilson, MDTaking people
About the trial
What the trial wants to find out
An artificial pancreas (AP) is a control system for automatic insulin delivery. The investigators have implemented a high blood sugar detection and dosing algorithm for use within an AP control system. If a high blood sugar pattern is detected, correction insulin will be calculated and delivered. The investigators will test how well the new algorithm manages glucose compared to the AP control system without high blood sugar detection and dosing. This type of algorithm may improve glucose control for high risk patient populations.
The group in the trial
- iPancreas automated insulin delivery systemTreatment being tested
Participants will use the iPancreas automated insulin delivery system for 4 weeks at home. After 3 weeks of collecting high blood sugar pattern data, the high blood sugar pattern detection and dosing feature will be turned on.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of a Fully-closed Loop AID System With a Context-aware Hyperglycemia Pattern Detection and Dosing Algorithm in People With Type 1 Diabetes
- Plain-language title
- Tests an automated insulin system for type 1 diabetes in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06676657, who can take part
- Record updated
- 11 April 2025